PE20241351A1 - Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40 - Google Patents

Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40

Info

Publication number
PE20241351A1
PE20241351A1 PE2024000811A PE2024000811A PE20241351A1 PE 20241351 A1 PE20241351 A1 PE 20241351A1 PE 2024000811 A PE2024000811 A PE 2024000811A PE 2024000811 A PE2024000811 A PE 2024000811A PE 20241351 A1 PE20241351 A1 PE 20241351A1
Authority
PE
Peru
Prior art keywords
monoclonal antibody
formula including
pharmaceutical formula
refers
pharmaceutical
Prior art date
Application number
PE2024000811A
Other languages
English (en)
Spanish (es)
Inventor
Qiang Sun
Xionghua Jin
Pengcheng Fan
Zhihao Xu
Original Assignee
Inmagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmagene Pte Ltd filed Critical Inmagene Pte Ltd
Publication of PE20241351A1 publication Critical patent/PE20241351A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2024000811A 2021-10-15 2022-10-13 Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40 PE20241351A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021124200 2021-10-15
CN2022118065 2022-09-09
PCT/CN2022/125017 WO2023061424A1 (en) 2021-10-15 2022-10-13 Pharmaceutical formulation comprising anti-ox40 monoclonal antibody

Publications (1)

Publication Number Publication Date
PE20241351A1 true PE20241351A1 (es) 2024-07-03

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000811A PE20241351A1 (es) 2021-10-15 2022-10-13 Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40

Country Status (13)

Country Link
US (1) US20250282882A1 (https=)
EP (1) EP4415754A4 (https=)
JP (1) JP2024538140A (https=)
KR (1) KR20240109250A (https=)
CN (1) CN118541166A (https=)
AU (1) AU2022367611A1 (https=)
CA (1) CA3235879A1 (https=)
CL (1) CL2024001157A1 (https=)
IL (1) IL312138A (https=)
MX (1) MX2024004619A (https=)
PE (1) PE20241351A1 (https=)
TW (1) TW202323280A (https=)
WO (1) WO2023061424A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230255A1 (es) * 2020-04-17 2023-02-07 Hutchison Medipharma Ltd Anticuerpo anti-ox40 y usos del mismo
TW202600166A (zh) * 2024-03-04 2026-01-01 新加坡商創響私人有限公司 包含ox40靶向抗體的藥物組合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
WO2020016417A1 (en) * 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
WO2020063668A1 (zh) * 2018-09-25 2020-04-02 信达生物制药(苏州)有限公司 包含抗ox40抗体的制剂、其制备方法及其用途
US20220273796A1 (en) * 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
WO2021190582A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种抗ox40抗体药物组合物及其用途

Also Published As

Publication number Publication date
MX2024004619A (es) 2024-07-12
TW202323280A (zh) 2023-06-16
CL2024001157A1 (es) 2024-11-15
WO2023061424A1 (en) 2023-04-20
AU2022367611A1 (en) 2024-05-02
KR20240109250A (ko) 2024-07-10
US20250282882A1 (en) 2025-09-11
IL312138A (en) 2024-06-01
EP4415754A1 (en) 2024-08-21
JP2024538140A (ja) 2024-10-18
CA3235879A1 (en) 2023-04-20
CN118541166A (zh) 2024-08-23
EP4415754A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
NI201900112A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
EA201792451A1 (ru) Антитела к ox40 и способы их применения
AR073720A1 (es) Anticuerpos humanizados de endoglina
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
CL2020003348A1 (es) Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes
PE20241351A1 (es) Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40
CO2019006073A2 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2017012694A (es) Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
MX2021004045A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti factor de crecimiento endotelial vascular (vegf) y un conjugado de anticuerpo anti factor tisular-farmaco.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
PE20230255A1 (es) Anticuerpo anti-ox40 y usos del mismo
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
CL2024003444A1 (es) Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano.
AR125815A1 (es) Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3